During Brain Awareness Week, we help the global effort to raise awareness about the importance of brain health and the impact of neurological disorders on millions of people worldwide.

Among these conditions, Alzheimer’s Disease is the leading cause of dementia and represents one of the most significant challenges facing healthcare systems as populations age. Detecting the disease early and developing effective treatments remain key priorities for researchers, clinicians and policymakers.

Alzheimer’s disease is one of SYNTHIA's six priority use cases, where we leverage synthetic data and artificial intelligence to advance research and innovation while ensuring patient privacy is protected.

Addressing Challenges in Alzheimer’s Disease Research

Alzheimer’s disease often begins many years before symptoms become visible. During these early stages, changes occur in the brain that are difficult to detect and interpret, making early diagnosis particularly challenging. Researchers rely on complex combinations of brain imaging, genetic data, fluid biomarkers and cognitive tests to understand disease progression. However, access to large and diverse datasets remains limited due to privacy regulations, fragmented data sources and the sensitivity of patient information.

The SYNTHIA Alzheimer's Disease teams (academic and industry partners) investigate how high-quality synthetic datasets can replicate the complexity of real clinical data, enabling researchers to train and test AI models without exposing identifiable patient information.

How Synthetic Data Supports Alzheimer’s Research

 

  • Earlier and more accurate diagnosis: By combining imaging data, genetic information, fluid biomarkers and neuropsychological tests, synthetic data can help strengthen AI models that distinguish between stages of cognitive decline, from normal cognition to mild cognitive impairment and dementia.
  • Strengthening clinical trials: Synthetic datasets generated from longitudinal cohort studies may help create realistic external control arms for clinical trials. This approach could reduce reliance on placebo groups and help accelerate the evaluation of new treatments.
  • Advancing brain imaging research: Synthetic data can augment MRI and PET imaging datasets, helping researchers improve models that estimate brain age, detect disease-related lesions and monitor disease progression.

Responsible Innovation for Brain Health

For neurological diseases such as Alzheimer’s, collaboration and access to high-quality data are essential to accelerate progress. At the same time, research must respect patient privacy and maintain public trust. By developing and validating synthetic data approaches, SYNTHIA aims to enable responsible data sharing, strengthen research collaborations and support the development of earlier diagnostics and more personalized treatment strategies.

During Brain Awareness Week, we reaffirm our commitment to advancing trustworthy AI and privacy-preserving data technologies that can help improve outcomes for people affected by Alzheimer’s disease.

View below an example of our campaign material.